Results 141 to 150 of about 468,060 (214)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Effectiveness of Metformin Prolonged-Release Formulation on Achievement of Optimal Glycemic Control in Gestational Diabetes Mellitus: Protocol for a Pilot, Randomized, Double-Blind, Clinical Trial. [PDF]

JMIR Res Protoc
Boriboonhirunsarn D, Sunsaneevithayakul P.   +1 more
europepmc   +1 more source

The New Strategy for Studying Drug-Delivery Systems with Prolonged Release: Seven-Day In Vitro Antibacterial Action. [PDF]

Molecules, 2022
Skuredina AA, Kopnova TY, Tychinina AS, Golyshev SA, Le-Deygen IM, Belogurova NG, Kudryashova EV.   +6 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Characterizing the Use of Prolonged-Release Once-Daily Tacrolimus (LCPT) across Canada. [PDF]

Can J Hosp Pharm
Phommavong V, Burger C, Shamseddin MK, Mansell H.   +3 more
europepmc   +1 more source

Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study. [PDF]

Pilot Feasibility Stud, 2023
Hard B, DeSilva M.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study. [PDF]

Clin Epigenetics
Cerda-Reyes E, de la Rosa-Bibiano R, Sandoval-Rodriguez A, Rosas-Campos R, Torre A, Cornejo-Hernández S, Escutia-Gutiérrez R, Vázquez-Esqueda Á, Gutierrez-Cuevas J, Gutiérrez-Átemis A, Amezquita-Pérez S, Poo JL, Garrido-Sánchez GA, Bastida-Alquicira J, Saldaña-Rivera E, Lozano-Trenado LM, Ramón-Aguilar J, Madrigal JA, Armendariz-Borunda J.   +18 more
europepmc   +1 more source

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report. [PDF]

Ther Adv Neurol Disord, 2022
Müller MKR, Christ M, Naumann M, Bayas A.   +3 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source